Skip to content

Opening book details…

Can I read Ps1378 An Early, Within The First Month, And Deep Response, Should Be The Goal Of Therapy In Al Amyloidosis on EtoBox?

Ps1378 An Early, Within The First Month, And Deep Response, Should Be The Goal Of Therapy In Al Amyloidosis by Kastritis, E.; Karatrasoglou, E. A.; Dialoupi, I.; Gavriatopoulou, M.; Roussou, M.; Fotiou, D.; Kanellias, N.; Ntanasis-Stathopoulos, I.; Eleutherakis-Papaiakovou, E.; Manios, E.; Migkou, M.; Papanota, A.-M.; Papadopoulou, E.; Stamatelopoulos, K.; Ntalianis, A.; Papanikolaou, A.; Psimenou, E.; Gakiopoulou, C.; Tsitsilonis, O.; Tselegkidi, M. E.; Trougakos, I.; Kostopoulos, I. V.; Terpos, E.; Dimopoulos, M. A. is a Medicine article available to read on EtoBox.

What is Ps1378 An Early, Within The First Month, And Deep Response, Should Be The Goal Of Therapy In Al Amyloidosis about?

24 th Congress of the European Hematology Association | 2019;3:S1 630 to progression, death or last F/U. We also calculated outcomes of relapsing patients in both arms, including 2 nd PFS (from second-line therapy to second relapse, death or last F/U) and PFS2 (time from induction therapy to second relapse, death or last F/U). Lastly, given regional variation in LM dosing schedules, we examined outcomes based on a 21/28 days or continuous 28/28 days dosing strategy. Results: Data from 1,256 patients across 10 Canadian centers was included (723 with LM and 533 without). Median follow-up in the LM group was 49 months and 45 months in the non-LM group. The median OS was not reached in the LM cohort and 98 months in the non-LM group (p <0.0001, figure 1a). The median PFS also favoured patients treated with LM (58 months versus 35 months respectively, p <0.0001, figure 1b). Response rates were high with 98% achieving ≥PR in the LM group compared to 96% in the non-LM group (p = 0.06). In LM patients 94% achieved ≥VGPR compared to 81% in the non-LM group (p <0.01). At the time of analysis, 45% of LM and 63% of non-LM patients have relapsed. Treatment for relapsed disease resulted in a sim

Who reads Ps1378 An Early, Within The First Month, And Deep Response, Should Be The Goal Of Therapy In Al Amyloidosis?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Kastritis, E.; Karatrasoglou, E. A.; Dialoupi, I.; Gavriatopoulou, M.; Roussou, M.; Fotiou, D.; Kanellias, N.; Ntanasis-Stathopoulos, I.; Eleutherakis-Papaiakovou, E.; Manios, E.; Migkou, M.; Papanota, A.-M.; Papadopoulou, E.; Stamatelopoulos, K.; Ntalianis, A.; Papanikolaou, A.; Psimenou, E.; Gakiopoulou, C.; Tsitsilonis, O.; Tselegkidi, M. E.; Trougakos, I.; Kostopoulos, I. V.; Terpos, E.; Dimopoulos, M. A.
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins; Ovid Technologies (Wolters Kluwer Health) (ISSN 2572-9241)
Published
2019
Language
EN
Field
Medicine (Health Sciences)

More by Kastritis, E.; Karatrasoglou, E. A.; Dialoupi, I.; Gavriatopoulou, M.; Roussou, M.; Fotiou, D.; Kanellias, N.; Ntanasis-Stathopoulos, I.; Eleutherakis-Papaiakovou, E.; Manios, E.; Migkou, M.; Papanota, A.-M.; Papadopoulou, E.; Stamatelopoulos, K.; Ntalianis, A.; Papanikolaou, A.; Psimenou, E.; Gakiopoulou, C.; Tsitsilonis, O.; Tselegkidi, M. E.; Trougakos, I.; Kostopoulos, I. V.; Terpos, E.; Dimopoulos, M. A.

Browse all works by Kastritis, E.; Karatrasoglou, E. A.; Dialoupi, I.; Gavriatopoulou, M.; Roussou, M.; Fotiou, D.; Kanellias, N.; Ntanasis-Stathopoulos, I.; Eleutherakis-Papaiakovou, E.; Manios, E.; Migkou, M.; Papanota, A.-M.; Papadopoulou, E.; Stamatelopoulos, K.; Ntalianis, A.; Papanikolaou, A.; Psimenou, E.; Gakiopoulou, C.; Tsitsilonis, O.; Tselegkidi, M. E.; Trougakos, I.; Kostopoulos, I. V.; Terpos, E.; Dimopoulos, M. A.